Fig. 1From: Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?Diagram of the indirect comparison between pembrolizumab plus chemotherapy vs. atezolizumab plus chemotherapy for advanced squamous non-small-cell lung cancer. Solid lines between treatment regimens represented the existence of direct comparisons. N = enrolled patient numberBack to article page